Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 129. Click on ID to see further detail.
| IDOV_414 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result35% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_415 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result35% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_416 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_417 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_418 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_419 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result21% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_420 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_421 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_422 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_423 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_424 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result8% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_425 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_438 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result88% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_439 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result46% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_440 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result62% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_441 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_442 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result26% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_443 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_444 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_445 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_446 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_447 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_448 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_449 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_450 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result90% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_451 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result58% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_452 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result74% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_453 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_454 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result28% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_455 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_456 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_457 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_458 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_459 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_460 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_461 | Virus nameAdenovirus | Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_462 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result56% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_463 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result58% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_464 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result24% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_465 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_466 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_467 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_468 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_469 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_470 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_471 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_472 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_473 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with CRAd (a deletion adenovirus mutant of 24 nucleotides (Δ24) in the E1A gene) | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result12% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_474 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result30% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_475 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration0.4 MOI | In-vitro result38% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_476 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result22% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_477 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration1 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_478 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result20% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_479 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration4 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_480 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result19% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_481 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration11 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_482 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_483 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration33 MOI | In-vitro result16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_484 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3ip.1 OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_485 | Virus nameAdenovirus | Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24) | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp). | Virus aloneNo | Virus in combination with drug/radiationViral starin in combination with ING4 | Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region | Source of cell lineATCC | Origin of cell lineHuman ovary cancer cell line | Cell lineSKOV3luc OvCa | Concentration of cell line3.0E+5 to 5.0E+5 cells per well | In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells | AssayMTS-based Cell Proliferation Assay (Promega) | In-vitro virus concentration100 MOI | In-vitro result14% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27349517 |
| IDOV_842 | Virus nameHerpes simplex virus | Virus strainHSV-G207 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant in ICP34.5 and ICPC6 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineEpithelial ovarian carcinoma | Cell lineSKOV3 | Concentration of cell line3.0E+3 cells per well | In-vitro toxicityMinimal cytotoxic to mesothelial cells | AssayBeta galacosidase colorimetric proliferation assay | In-vitro virus concentration0.01 MOI | In-vitro result35% cancer cell killing | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID10770637 |
| IDOV_4711 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.001 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4712 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4713 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4714 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4715 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result50% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4726 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.001 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4727 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4728 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4729 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result75% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4730 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result65% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4741 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.001 MOI | In-vitro result5% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4742 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result4% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4743 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result3% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4744 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result3% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4745 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result1% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4755 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4756 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4757 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4758 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4767 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4768 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4769 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result75% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4770 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result75% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4779 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.01 MOI | In-vitro result30% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4780 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration0.1 MOI | In-vitro result15% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4781 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration1 MOI | In-vitro result15% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4782 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result15% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4802 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4803 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4804 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result60% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4805 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result80% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4806 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result70% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4807 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result20% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4808 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result60% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4809 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result40% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4810 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result10% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4811 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result60% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4812 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result20% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4813 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result1% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4814 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result50% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4815 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result2% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4816 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result2% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4847 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4848 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4849 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result80% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4850 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4851 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4852 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result40% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4853 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4854 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result90% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4855 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result10% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4856 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4857 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result70% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4858 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result20% cell viability after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4859 | Virus nameMyxoma virus | Virus strainwild type | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result100% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4860 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result60% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_4861 | Virus nameMaraba virus | Virus strainwild type | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line50000 cells per well | In-vitro toxicityNA | AssayCell titer Glo luminiscent assay | In-vitro virus concentration10 MOI | In-vitro result20% cell viability after 5 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID27119108 |
| IDOV_5071 | Virus nameAvian orthoreovirus | Virus strainARV-PB1 | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman epithelial ovarian carcinoma | Cell lineSKOV3 | Concentration of cell line1.0E+3 cells per well | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result70% cell viability after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectInduction of Interferon related gene expression | Clinical trialNA | PMID28441762 |
| IDOV_5305 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration0.1 PFU | In-vitro result100% cell viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5306 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration0.33 PFU | In-vitro result98% cell viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5307 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration1 PFU | In-vitro result50% cell viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5308 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration3.3 PFU | In-vitro result18% cell viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5309 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration10 PFU | In-vitro result15% cell viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5310 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration33 PFU | In-vitro result100% cell killing | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5311 | Virus nameHerpes simplex virus | Virus strainM032 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeVirus expressing murine IL-12 | Source of cell lineNA | Origin of cell lineHuman ovarian cancer cell line | Cell lineSKOV3 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayAlamar blue assay | In-vitro virus concentration100 PFU | In-vitro result100% cell killing | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectTumor specific T cell response induced | Clinical trialNA | PMID27784340 |
| IDOV_5611 | Virus nameNewcastle disease virus | Virus strainNDV-MK107 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian sarcoma cell line | Cell lineSKOV3 | Concentration of cell line80% confluency | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration24 pfu | In-vitro result50% of cancer cell death occurs | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis by virus infection | Immunogenic effectInduction of IFN-Gamma production | Clinical trialNA | PMIDUS7470426 |
| IDOV_5830 | Virus nameNewcastle disease virus | Virus strainNDV-PPMK107 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman ovarian carcinoma cell line | Cell lineSKOV3 | Concentration of cell line80% confluency | In-vitro toxicityNA | AssayNA | In-vitro virus concentration24 pfu | In-vitro result50% cancer cell death | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMIDUS8105578 |
| IDOV_5892 | Virus nameAdenovirus | Virus strainCGTG-602 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationVirus E1A promoter is replaced by human E2F1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman ovarian carcinoma cell line | Cell lineSKOV3 | Concentration of cell lineNA | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 ×10ⴠpfu | In-vitro result80% of cancer cell death occurs after 100 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMIDUS9410129 |